THURSDAY, July 15, 2021 (HealthDay News) — An active mind in old age may delay Alzheimer’s disease by up to five years, a new study suggests. Activities like reading, writing letters, playing cards or doing puzzles may prolong brain health even for those in their 80s, researchers say. “The key
TUESDAY, July 13, 2021 (Healthday News) — Medicare launched a formal process on Monday that will determine whether the agency will cover Aduhelm, the newly approved Alzheimer’s drug whose high price tag and unproven benefits have prompted widespread controversy. Medicare’s announcement came the same day that leaders of two House
MONDAY, July 12, 2021 (Healthday News) — The U.S. Food and Drug Administration’s controversial approval of the Alzheimer’s drug Aduhelm should be investigated by the Office of Inspector General (OIG), FDA Acting Commissioner Dr. Janet Woodcock has said. The FDA approved Aduhelm even though an advisory panel of outside experts
THURSDAY, July 8, 2021 (HealthDay News) — The U.S. Food and Drug Administration on Thursday issued new prescribing rules for the controversial Alzheimer’s medication Aduhelm that will likely limit its use. When first approved a month ago, the FDA said Biogen’s monthly IV drug was for all Alzheimer’s patients. The
THURSDAY, July 1, 2021 (Healthday News) — The U.S. Food and Drug Administration’s controversial approval of a new Alzheimer’s drug, along with its high price, is now being investigated by two House committees. “We have serious concerns about the steep price of Biogen’s new Alzheimer’s drug Aduhelm and the process
TUESDAY, June 29, 2021 (HealthDay News) — Alzheimer’s disease has no cure, but one expert says it may be possible to reduce the risks of developing the disease with healthy lifestyle changes. There are two different types of Alzheimer’s. Early-onset typically affects patients before age 65. Late-onset affects older adults.
MONDAY, June 28, 2021 (HealthDay News) — Most Americans with dementia are undiagnosed, which shows how important it is to screen and assess seniors for the disease, researchers say. Their new analysis of data from a nationwide survey of about 6 million Americans aged 65 and older revealed that 91%
FRIDAY, June 25, 2021 (Healthday News) — Fresh on the heels of the U.S. Food and Drug Administration’s approval of the controversial Alzheimer’s drug Aduhelm, the maker of a second medicine that works in similar fashion said Thursday it hopes to apply for approval of its medication later this year.
TUESDAY, June 22, 2021 (HealthDay News) — The brains of people who died from COVID-19 were remarkably similar to the brains of people who die from neurodegenerative diseases such as Alzheimer’s and Parkinson’s, showing inflammation and disrupted circuitry, researchers report. “The brains of patients who died from severe COVID-19 showed
MONDAY, June 14, 2021 (HealthDay News) — An experimental Alzheimer’s vaccine appears to safely clear abnormal tau protein from the brain, but it’s not yet clear whether the shot will be able to save brain function. In a Phase 2 clinical trial, the vaccine produced high levels of antibodies to
MONDAY, June 7, 2021 (HealthDay News) — The U.S. Food and Drug Administration has approved the first new drug to treat Alzheimer’s disease in nearly two decades, in a controversial decision that left the agency defending its reputation and its science. Aduhelm (aducanumab) treats Alzheimer’s by clearing out amyloid beta,
MONDAY, June 7, 2021 (HealthDay News) — The first new Alzheimer’s drug in nearly two decades was approved by the U.S. Food and Drug Administration on Monday, despite opposition from the agency’s own independent advisory committee and some experts who said there wasn’t enough proof the drug could actually help
THURSDAY, May 27, 2021 (HealthDay News) — The U.S. government and nonprofits are replacing drug companies as the main drivers of Alzheimer’s disease research, two new studies show. The findings are from an analysis of national data by Jeffrey Cummings, a research professor at the University of Nevada, Las Vegas